Seurat Therapeutics is developing insulin-like growth factor-1 (IGF-1) for intranasal delivery using a medical device. The company is developing this platform for targeted delivery of insulin-like growth factor-1 (IGF-1) to the nervous system for treatment of disabling and burdensome neurological disorders. The scientific rationale underlying Seurat Therapeutics’ development of insulin-like growth factor-1 (IGF-1) as a treatment for these disorders came from the observation that actively participating in environmental enrichment such as exercise, hiking, cognitive puzzles, increases nervous system levels of insulin-like growth factor-1 (IGF-1), and substantially alleviates symptoms of various neurological disorders. By combining the understanding of the environmental enrichment phenomena with innovative research methods, scientists have uncovered a novel approach for treating various neurological diseases.